Patents for A61P 35 - Antineoplastic agents (221,099)
01/2007
01/11/2007WO2006009734A8 Gonadotropin releasing hormone receptor antagonists
01/11/2007WO2005025620A3 Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
01/11/2007US20070010669 Novel class of cytodifferentiating agents and histone deacetylase inhibitors, and methods of use thereof
01/11/2007US20070010668 antineoplastic/antimitotic agents; inhibit proliferation of the cell; breast cancer, colon cancer, lung cancer, prostate cancer, lymphoma, leukemia, endometrial cancer, melanoma; Polo-like kinase inhibitors; 2-({5-nitro-2-[(3,4,5-trimethoxyphenyl)amino]pyrimidin-4-yl}amino)benzoic acid hydrochloride
01/11/2007US20070010575 Intracorporeal medicaments for photodynamic treatment of disease
01/11/2007US20070010574 Use of a trpm8-activating substance for the treatment of tumours
01/11/2007US20070010570 Medical Compositions for Intravesical Treatment of Bladder Cancer
01/11/2007US20070010569 4-Methyl-5-(2-oxo-1,2-dihydroindol-3- ylidenemethyl)-1H-pyrrole-2- carboxylic acid; cancer
01/11/2007US20070010560 Benzimidazole derivatives as raf kinase inhibitors
01/11/2007US20070010536 Selectively inducing terminal differentiation of neoplastic cells; antiproliferative agents; antineoplastic agents; antitumor agents; melanomes; acute leukemia, multiple myeloma; carcinomas; neuroblastoma; N-t-butoxycarbonyl- omega -methyl - alpha -aminosuberateanilide
01/11/2007US20070010534 Novel compounds
01/11/2007US20070010529 Nitrogenous heterocyclic compounds and medical use thereof
01/11/2007US20070010515 [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof
01/11/2007US20070010483 Glucocerebroside treatment of liver disorders
01/11/2007US20070010476 Therapy and diagnosis of conditions related to telomere length and/or telomerase activity
01/11/2007US20070010473 Nucleic acid ligands to integrins
01/11/2007US20070010472 Oligonucleotide compositions and their use to induce differentiation of cells
01/11/2007US20070010457 Caspase inhibitors and uses thereof
01/11/2007US20070010432 Heat shock protein 90 activator
01/11/2007US20070010430 Proteoglycan isolated from cartilaginous fish and process for producing the same
01/11/2007US20070009964 competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells
01/11/2007US20070009946 Retrieving ductal fluid samples from ducts using elongated lumen and detecting presence of papilloma, Epstein-barr and herpes virus
01/11/2007US20070009892 Method of preparing epitopes chimeric gene vaccine
01/11/2007US20070009538 Expression and export of angiogenesis inhibitors as immunofusins
01/11/2007US20070009522 administering to an Rh-negative individual in need of an anti-Rh(D) monoclonal antibody, wherein monoclonal antibody exhibits a Fc gamma RTIII-type ADCC ( antibody-dependent cell-mediated cytotoxicity (ADCC) assays) level greater than 80% relative to a reference polyclonal anti-Rh(D) human antibody
01/11/2007US20070009519 Immunoregulatory Antibodies and Uses Thereof
01/11/2007US20070009513 Novel method of screening
01/11/2007US20070009509 Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor
01/11/2007US20070009487 Minimal promoters and uses thereof
01/11/2007US20070009433 14094, a novel human trypsin family member and uses thereof
01/11/2007DE4342092B4 Langwirkende Injektionssuspension und Verfahren zur Herstellung Long-acting injection suspension and process for producing
01/11/2007DE102005031780A1 Use of aromatase inhibitor for treatment and/or prevention of cancers, e.g. breast cancer and its metastases
01/11/2007DE102005028862A1 Substituierte Heterocyclen, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen Substituted heterocycles, their use as a medicament as well as pharmaceutical compositions containing them
01/11/2007CA2650656A1 Cytokine receptor modulators and uses thereof
01/11/2007CA2614315A1 Activator of peroxisome proliferator activated receptor d
01/11/2007CA2614148A1 Pyrimidine-substituted benzimidazole derivatives as protein kinase inhibitors
01/11/2007CA2614102A1 Core 2 glcnac-t inhibitors
01/11/2007CA2614084A1 Treatment of tumors
01/11/2007CA2614080A1 Anti-ccr7 receptor antibodies for the treatment of cancer
01/11/2007CA2614002A1 Combination therapy of cancer with azd2171 and gemcitabine
01/11/2007CA2613895A1 Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
01/11/2007CA2613664A1 2,4-diamino-pyrimidines used as aurora inhibitors
01/11/2007CA2613428A1 5,6-di-substituted oxadiazolopyrazines and thiadiazolopyrazines as cxc-chemokine receptor ligands
01/11/2007CA2613322A1 Methods of modulating smyd3 for treatment of cancer
01/11/2007CA2613211A1 Pyrroloquinoline derivatives and their use as protein kinase inhibitors
01/11/2007CA2613059A1 Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect, process for their manufacture and use thereof as medicaments
01/11/2007CA2612241A1 Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
01/11/2007CA2611688A1 Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
01/10/2007EP1742059A1 Use of PTA peptides for stratification of individuals having cancer
01/10/2007EP1742052A1 Method for testing effect of angiogenesis inhibitor via integrin expression inhibition
01/10/2007EP1741780A2 High affinity oligonucleotide ligands to growth factors
01/10/2007EP1741722A2 Polymorphisms in the human P2X7 gene
01/10/2007EP1741716A1 Process for producing pentacyclic taxane
01/10/2007EP1741715A1 Epothilone derivatives and their synthesis and use
01/10/2007EP1741714A1 Heterocyclic compound and anti-malignant-tumor agent containing the same as active ingredient
01/10/2007EP1741713A2 Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
01/10/2007EP1741703A1 Pyridone derivative
01/10/2007EP1741702A1 Nitrogen-containing heterocyclic compounds and medicinal use thereof
01/10/2007EP1741697A1 Crystal comprising (2r)-2-propyloctoic acid and amine
01/10/2007EP1741449A1 Preventive and/or remedy for cancer
01/10/2007EP1741441A1 Bone densifying agent characterized by use of cathepsin k inhibitor with pth
01/10/2007EP1741438A1 Pharmaceutical preparation containing bacterial cell wall skeleton component
01/10/2007EP1740616A1 Anti-tfr antibody.
01/10/2007EP1740591A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
01/10/2007EP1740579A1 Tricyclic pyrazole kinase inhibitors
01/10/2007EP1740576A1 Novel piperidine substituted diaminothiazoles
01/10/2007EP1740541A2 Therapeutic formulations of desoxyepothilones
01/10/2007EP1740212A2 Pharmaceutical compositions comprising beta-carboline derivatives and use thereof for the treatment of cancer
01/10/2007EP1740209A2 Method and system to remove soluble tnfr1, tnfr2, and il2 in patients
01/10/2007EP1740184A1 Combinations of signal transduction inhibitors
01/10/2007EP1740182A2 Use of 5,10-methylene tetrahydrofolate for the treatment of cancer
01/10/2007EP1740173A1 Azabicyclo-octane inhibitors of iap
01/10/2007EP1740170A2 Combination therapy with azd2171 and platinum anti-tumour agent
01/10/2007EP1680425B1 6- [(substituted)phenyl] triazolopyrimidines as anticancer agents
01/10/2007EP1521583B1 7,8,9,10-tetrahydro-6h-azepino, 6,7,8,9-tetrahydro-pyrido and 2,3-dihydro-2h-pyrrolo (2,1-b)-quinazolinone derivatives
01/10/2007EP1443927B1 Carboline derivatives as inhibitors of ikb in the treatment of multiple myeloma
01/10/2007EP1418915B1 Neuroprotective drug
01/10/2007EP1417227B1 Peptides eefective in the treatment of tumors and other conditions requiring the removal or destruction of cells
01/10/2007EP1416885B1 Devices for delivery of therapeutic agents with variable release profile
01/10/2007EP1414440B1 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
01/10/2007EP1313491B1 Bioactive fraction of eurycoma longifolia
01/10/2007EP1305051A4 Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
01/10/2007EP1301534B1 Mutated pf-4, its fragments and mutated fusion peptides, their analogues, corresponding dna, cdna and mrna sequences and their use for inhibiting angiogenesis
01/10/2007EP1232180B1 Polypeptides derived from vitamin d nuclear receptor, and their uses in particular for screening vitamin d analogues
01/10/2007EP1194147B1 Arylthiazolidinedione and aryloxazolidinedione derivatives
01/10/2007EP1176984B1 Medicament vehicle for the controlled administration of an active agent, produced from lipid matrix-medicament conjugates
01/10/2007EP1087946B1 Aryl alkanoylpyridazines
01/10/2007EP1078060B1 Antibodies to dendritic cells and human dendritic cell populations and uses thereof
01/10/2007EP1017723B1 Costimulating t-cell polypeptide, monoclonal antibodies, their preparation and use
01/10/2007EP0866709B1 1,2,4-benzotriazine oxides formulations
01/10/2007CN1894344A Compounds for dual photodiagnosis and therapy
01/10/2007CN1894278A Akt activity specifically inhibiting polypeptide
01/10/2007CN1894271A Glycosylated steroid derivatives with anti-migratory activity
01/10/2007CN1894264A Organophosphorous indazole derivatives and use thereof as protein kinase inhibitors
01/10/2007CN1894260A Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
01/10/2007CN1894245A Pyrido[2,3-d]pyrimidine-2,4-diamines as PDE2 inhibitors
01/10/2007CN1894244A Aryl ether substituted imidazoquinolines
01/10/2007CN1894243A 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
01/10/2007CN1894210A Prolinylarylacetamides
01/10/2007CN1894195A Ether compounds and compositions for cholesterol management and related uses